Latest news with #ChrisBroderick
Yahoo
15-07-2025
- Business
- Yahoo
Merakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation Showcase
MTX-001, an investigational new drug, aims to become the first subcutaneous biologic drug therapy for chronic non-healing venous leg ulcers RESEARCH TRIANGLE PARK, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces its amniotic fluid-derived regenerative biologic, MTX-001, an investigational new drug, is a finalist for the Innovation Showcase: Early-Stage Disruptors in Wound Care at the 2025 Advanced Wound Care (AWC) Summit in Boston. Only six companies were chosen by the AWC selection committee to present at the event on July 17, 2025 at 8:30am ET. At the Innovation Showcase, Chris Broderick, Merakris Therapeutics CEO, will present an overview of MTX-001, including promising key findings from the ongoing Phase 2 clinical trial evaluating the therapy in patients with non-healing venous leg ulcers (VLUs) also referred to as venous stasis ulcers (VSUs). 'Non-healing VLUs affect millions of people and a substantial number of patients fail to heal with today's standard therapies,' said Broderick. 'MTX-001 represents a new class of regenerative biologics delivered via subcutaneous injection. This innovation is proving to promote healing in chronic venous wounds and improve patient outcomes.' Also at the 2025 Advanced Wound Care Summit, Sean O'Connell, PhD, Head of Medical Affairs at Merakris Therapeutics, will present 'Injectable Drugs as the Next Big Step for Advanced Wound Care' on July 16th at 3:15pm. His talk will review the MTX-001 clinical program, interim Phase 2 results, and outline upcoming plans for a Phase 3 clinical trial. He will also highlight the unmet needs in the chronic wound market and the emerging role of injectable biologics in outpatient care. For strategic partnership and collaboration opportunities, please visit For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. CONTACT: PR Contact: Garth Miller Nova Marketing Solutions 919-923-3505Sign in to access your portfolio
The Sun
04-06-2025
- Entertainment
- The Sun
Legendary metal band shock fans as member exits after seven years
MUSIC fans have been left reeling following one member's shock departure from a legendary metal band. Supporters of the group are in shock after the drummer downed his sticks and walked away just days before their massive European tour. 5 5 In Flames announced the news on the band's social media accounts, telling fans they had "parted ways" with Tanner Wayne. In a statement released on Instagram, In Flames said: "It is with profound gratitude and and appreciation that we announce our creative decision to part ways with Tanner Wayne. "His dedication and musicianship over the past several years has left, and will continue to leave, a lasting mark on this band. "We wish him nothing but the best." The Swedish band, which was formed 35 years ago, concluded: "We appreciate your support and understanding at this time and hope to see you all on tour this summer." Tanner, 37, joined In Flames in July 2018 when he replaced drummer Joe Rickard. The US musician had begun his drumming career in the hardcore punk band Underminded in 2006, but only featured on one album. He went on to drum for Chiodos and Suicide Silence before his seven-year stint with In Flames. Tanner's shock exit from the band came just days before they kicked off their European tour in Estonia. For the next month, the group - consisting of Björn Gelotte, Anders Fridén, Chris Broderick and Liam Wilson - will be performing across central Europe, eventually wrapping up Sweden. But despite Tanner walking away, the shows will go on. In Flames has already recruited a new drummer who accompanied them on their opening night in Tallin, Estonia, on Monday. Jon Rice has stepped in for the band's high profile tour and appears to have slotted right in. Alongside a photo of himself playing on stage, Jon wrote on Instagram: "Show #1 done. Thank you for the warm welcome, Tallinn. "And thank you to @inflames for having me and trusting me with your tunes." In Flames was originally formed by guitarist Jesper Strömblad in Gothenburg out of the Swedish death metal scene in 1990. The lineup has changed multiple times over the past three decades, however vocalist Anders Fridén and guitarist Björn Gelotte have remained consistent since 1995. 5 5
Associated Press
26-03-2025
- Health
- Associated Press
International Wound Journal Publishes Positive Phase 2 Interim Data on Cell-free Amniotic Fluid Injectable Biologic for the Treatment of Venous Leg Ulcers
RESEARCH TRIANGLE PARK, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced the publication of positive clinical trial results from the first part of its ongoing Phase 2, multicenter trial. This study evaluates its biological drug, MTX-001 (Dermacyte Liquid), a cell-free amniotic fluid (cfAF) for chronic, non-healing venous leg ulcers (VLUs). Interim results from part one of the study published in the International Wound Journal, highlights the investigational new drug's potential as a first-in-class biologic therapy in nine patients completing study treatment with lower extremity venous wounds refractory to healing using standard-of-care-based approaches. Key Findings: Wound Duration Prior to Treatment: Prior to injection therapy, the patients' VLUs persisted for a median duration of 7 months despite correcting the underlying venous reflux and standard-of-care interventions. Pain Reduction: Mean pain scores were significantly reduced by the study end. Total Wound Closure: 66.7% of patients achieved complete wound closure by the one-month post-trial follow-up. Wound Area Reduction: The average percent reduction of ulcer area was 83.7% in patients that completed the 12-week treatment duration. Long-Term Chronic Wounds Treated: The average duration of ulcers before study enrollment was 73 weeks, emphasizing the challenge of treating these cases with standard care alone. 'These results are highly encouraging, particularly given the long-standing, non-healing nature of the wounds treated in this study and support the growing body of evidence demonstrating efficacy and safety of this novel subcutaneous biologic for chronic venous leg ulcers,' said Chris Broderick, Merakris' CEO. 'MTX-001 represents an innovative therapeutic approach to significantly improving outcomes for patients suffering from chronic, recalcitrant venous leg ulcers, and if approved, could be a cost-effective therapy.' Addressing a Critical Unmet Need in Venous Wound Care Chronic venous insufficiency (CVI) affects millions of Americans, with up to 3% of adults in the United States developing severe venous leg ulcers (VLUs). While 60% of VLUs typically heal within 12 weeks, recurrence rates remain alarmingly high — 30% within one year and up to 70% within two years. Advancing Innovation in Wound Healing The primary objectives of the first part of this ongoing Phase 2 trial were to evaluate the safety and tolerability of MTX-001 while gaining insights into dosing frequency and efficacy metrics such as: Complete wound closure Reduction of wound size Pain relief (VAS score) Improved quality of life (HR-QoL) 'To our knowledge, this is the first multi-patient clinical trial evaluating cfAF therapy for chronic, non-healing VLUs,' added Chris Broderick. 'The data suggest that MTX-001 is safe, well-tolerated, and effective in patients who have undergone correction of underlying venous reflux disease. These findings support its potential role in reducing clinical burden, improving healing rates, and enhancing patient quality of life.' Next Steps: Enrollment Open for Phase 2 Part 2 Merakris has opened patient enrollment for Part 2 of this Phase 2 clinical trial ( NCT04647240) to further assess the efficacy and safety of MTX-001. For more information on the venous leg ulcer study or Merakris' expanded access drug program, please contact the medical affairs team at [email protected]. About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. PR Contact:
Yahoo
26-03-2025
- Health
- Yahoo
International Wound Journal Publishes Positive Phase 2 Interim Data on Cell-free Amniotic Fluid Injectable Biologic for the Treatment of Venous Leg Ulcers
Results from Part 1 of a two-part Phase 2 clinical trial demonstrate the efficacy and safety of a novel subcutaneous biologic for chronic venous leg ulcers RESEARCH TRIANGLE PARK, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced the publication of positive clinical trial results from the first part of its ongoing Phase 2, multicenter trial. This study evaluates its biological drug, MTX-001 (Dermacyte Liquid), a cell-free amniotic fluid (cfAF) for chronic, non-healing venous leg ulcers (VLUs). Interim results from part one of the study published in the International Wound Journal, highlights the investigational new drug's potential as a first-in-class biologic therapy in nine patients completing study treatment with lower extremity venous wounds refractory to healing using standard-of-care-based approaches. Key Findings: Wound Duration Prior to Treatment: Prior to injection therapy, the patients' VLUs persisted for a median duration of 7 months despite correcting the underlying venous reflux and standard-of-care interventions. Pain Reduction: Mean pain scores were significantly reduced by the study end. Total Wound Closure: 66.7% of patients achieved complete wound closure by the one-month post-trial follow-up. Wound Area Reduction: The average percent reduction of ulcer area was 83.7% in patients that completed the 12-week treatment duration. Long-Term Chronic Wounds Treated: The average duration of ulcers before study enrollment was 73 weeks, emphasizing the challenge of treating these cases with standard care alone. 'These results are highly encouraging, particularly given the long-standing, non-healing nature of the wounds treated in this study and support the growing body of evidence demonstrating efficacy and safety of this novel subcutaneous biologic for chronic venous leg ulcers,' said Chris Broderick, Merakris' CEO. 'MTX-001 represents an innovative therapeutic approach to significantly improving outcomes for patients suffering from chronic, recalcitrant venous leg ulcers, and if approved, could be a cost-effective therapy.' Addressing a Critical Unmet Need in Venous Wound Care Chronic venous insufficiency (CVI) affects millions of Americans, with up to 3% of adults in the United States developing severe venous leg ulcers (VLUs). While 60% of VLUs typically heal within 12 weeks, recurrence rates remain alarmingly high — 30% within one year and up to 70% within two years. Advancing Innovation in Wound Healing The primary objectives of the first part of this ongoing Phase 2 trial were to evaluate the safety and tolerability of MTX-001 while gaining insights into dosing frequency and efficacy metrics such as: Complete wound closure Reduction of wound size Pain relief (VAS score) Improved quality of life (HR-QoL) 'To our knowledge, this is the first multi-patient clinical trial evaluating cfAF therapy for chronic, non-healing VLUs,' added Chris Broderick. 'The data suggest that MTX-001 is safe, well-tolerated, and effective in patients who have undergone correction of underlying venous reflux disease. These findings support its potential role in reducing clinical burden, improving healing rates, and enhancing patient quality of life.' Next Steps: Enrollment Open for Phase 2 Part 2 Merakris has opened patient enrollment for Part 2 of this Phase 2 clinical trial (NCT04647240) to further assess the efficacy and safety of MTX-001. For more information on the venous leg ulcer study or Merakris' expanded access drug program, please contact the medical affairs team at medaffairs@ About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. PR Contact:Garth MillerNova Marketing
